NEW PICK COMING SOON: LAST TWO PICKS SURGED HIGHER ON RECORD VOLUME; SIGN UP FOR OUR FREE NEWSLETTER ABOVE TO BE AMONG THE FIRST TO RECEIVE OUR NEXT WINNING PICK!
Hi Everyone & Welcome New Subscribers,
NVLX – Potential Continued Momentum/Volume – (Nuvilex, Inc.) – closed up 29.83%, at .2999 a share, on more than 39.4 million shares traded Friday. Nuvilex, Inc. is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer and diabetes built on a proprietary cellulose-based live-cell encapsulation platform, known as Cell-in a-Box(TM), that is therapeutically valuable. Just last week, NVLX announced that they had entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park), a Chicago-based institutional investor. Lincoln Park initially purchased 8 million shares of Nuvilex’s common stock at $0.25 per share for $2 million and has committed to invest, at the sole option of Nuvilex, up to an additional $25 million of equity capital over the term of the purchase agreement. Read the full story, HERE. Shares of NVLX surged last week following this news, and for good reason, considering the recent $2M investment at .25, which was below where the stock traded most of the week. It’s possible NVLX starts to establish a floor near this price over the coming days, but after closing just off Friday’s high on all-time record volume, it could be in for one more big day Monday. Keep it on close watch.
BIEL – Potential Continued Momentum/Volume – (BioElectronics Corp.) – closed up a whopping 460.00%, at .0028 a share, on more than 1.2 billion shares traded Friday. BioElectronics Corporation develops, manufactures, markets and sells consumer medical electronic devices that have both a high efficacy and safety profile for acute and chronic pain. Along with the added benefit of an unmatched cost/benefit ratio, the Company’s innovative, miniaturized technology contains an embedded microchip and battery that deliver pulsed electromagnetic field energy, a clinically proven and widely accepted anti-inflammatory and pain relief therapy that has only been possible to obtain from large, facility-based equipment. BIEL announced Friday, before the market opened, their excitement over the FDA’s recent recla
ssification of shortwave medical devices (which BIEL focuses on specifically for drug-free pain relief applications) to class II, which was received extremely well by investors. Read the full press release, HERE. BIEL traded a record amount of shares following this news, and closed just below Friday’s high of .003, which it might open over tomorrow. Keep it on close watch for a move higher tomorrow, or over the coming weeks following this volume off what appears to be a price bottom near .001.
Sign Up-> HERE <-To Be Among The First To Receive Our Next Winning Pick!
The Penny Stock Experts Team at Todayspickis.com
Please read our legal Disclaimer below: This disclaimer is to be read in its entirety, and fully understood before using Todayspickis.com or joining the email list.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS.Neither Todayspickis.com nor any of its employees, affiliates, subsidiaries, or family members are registered investment advisers or registered stock brokers either within the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority and shall not be liable for any direct, indirect, incidental, special or consequential damages arising out of, or resulting from the use or inability to use this site, including but not limited to damages for the loss of capital, funds, profits, use, data, or any and all other possible damages, even if such party has been advised of the possibility of such damages resulting from the use of this site and all information contained on this site. We are neither licensed nor qualified to provide investment advice.
The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the company’s profiled based solely on information contained in our newsletter or website. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research.
Todayspickis.com may buy or sell shares on the open market that may positively or negatively affect the stock price before or after this mailing and subscribers are to be fully aware that Todayspickis.com and it’s affiliates can buy or sell more shares at any time. Todayspickis.com and/or it’s affiliates may receive compensation for e-mail alerts. To view our full compensation disclosure please visit www.Todayspickis.com/Disclaimer.html. Todayspickis.com does not accept free-trading shares as a form of payment.